Biotech of the week: Kiadis Pharma, Immuno-therapy made in Amsterdam


This week we say ‘auf Wiedersehen’ to Germany and head West to the Netherlands and it’s capital city, Amsterdam. This city really does have it all, whether you’re looking for history, architecture or something more indulgent… it is also the location of our biotech of the week: Kiadis Pharma

City: Amsterdam, Netherlands

Founded: 1997

Employees: 23 (as of 12/2015)

Financial Data: €167.3M Market Cap (as of 10/12/2015)


Manfred Rüdiger, CEO CC Kiadis Pharma

Manfred Rüdiger, CEO CC Kiadis Pharma

Mission: Kiadis Pharma‘s main mission is to become a leading biopharma in the research, development and commercialisation of therapeutic products in cell-based immunotherapy. They plan to achieve this by focusing on 2 main areas, leukaemia and thalassemia. At present, they have 2 product candidates, ATIR101 in blood cancers, which is currently in phase II clinical trials and ATIR201 in thalassemia, which is predictved to enter clinical development early 2016. Kiadis hope these products will provide a more effective treatment for those with these diseases, at the same time as improving survival rate and quality of life.

Comments: 2015 has definitely been the year of immuno-therapy. Big Pharma has never done as many deals, the field has never raised as much money, and this has ultimately helped everyone. Kiadis has also profited from it, and will probably continue to do so as immuno-therapy should be still overly hype in 2016. And with Phase II results to come, this could lead to a potentially positive announcement.

Let's Continue The Conversation

Feel free to send us comments about this article to and/or comment on that article on social media.

We use cookies to give you the best experience and for advertising purposes. By accepting, you support our independent media and it's freely accessible content.